Compugen Ltd (CGEN)

5.95
NASDAQ : Health Care
Prev Close 5.85
Day Low/High 5.80 / 6.10
52 Wk Low/High 4.32 / 7.57
Avg Volume 125.60K
Exchange NASDAQ
Shares Outstanding 50.91M
Market Cap 297.81M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Compugen To Host R&D Day On December 7, 2016 In New York

Compugen To Host R&D Day On December 7, 2016 In New York

Event to focus on the Company's immuno-oncology programs; Live webcast will be available via the Company's website

Compugen Third Quarter Financial Statements To Be Released November 7, 2016

Compugen Third Quarter Financial Statements To Be Released November 7, 2016

Third quarter conference call postponed to November 16 to allow discussion of new CGEN-15029 data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer

Compugen To Present At The Annual Meeting Of The Society For Immunotherapy Of Cancer Next Month

Compugen To Present At The Annual Meeting Of The Society For Immunotherapy Of Cancer Next Month

Presentation will include new data on CGEN-15029, a Compugen-discovered novel immune checkpoint target, including functional characterization and antibody blockade

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Discloses Development Of Enhanced LINKS Platform Utilized For The Discovery Of Myeloid Targets For Cancer Immunotherapy

Compugen Discloses Development Of Enhanced LINKS Platform Utilized For The Discovery Of Myeloid Targets For Cancer Immunotherapy

Myeloid target candidates predicted in silico using enhanced LINKS platform are now being experimentally validated

Compugen Discloses Lead Therapeutic Candidate For CGEN-15029 Immuno-Oncology Program

Compugen Discloses Lead Therapeutic Candidate For CGEN-15029 Immuno-Oncology Program

IND filing for COM701 anticipated next year

Compugen Enters Oversold Territory (CGEN)

Compugen Enters Oversold Territory (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

When you get an unexpected rally, just go with it, Cramer says.

Compugen Presents Results For CGEN-15029 Immuno-Oncology Therapeutic Program

Compugen Presents Results For CGEN-15029 Immuno-Oncology Therapeutic Program

Multiple blocking antibodies discovered for Compugen novel immune checkpoint target candidate for treatment of cancer

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Compugen

Relative Strength Alert For Compugen

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, announced today that it has achieved the third preclinical milestone pursuant to its cancer immunotherapy collaboration with Bayer HealthCare...

Stocks to Watch for 2016 M&A Deals

Look for 2015's record run of mergers and acquisitions to continue.

Compugen To Present At The Oppenheimer Healthcare Conference In New York

Compugen To Present At The Oppenheimer Healthcare Conference In New York

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial Officer of Compugen, will present a corporate overview and update at the Oppenheimer 26th Annual...

Compugen To Present At Jefferies 2015 Global Healthcare Conference In London

Compugen To Present At Jefferies 2015 Global Healthcare Conference In London

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Dr.

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the third quarter ending September 30, 2015.

Compugen Third Quarter 2015 Conference Call Scheduled For Tuesday, November 3, 2015 At 10:00 AM ET

Compugen Third Quarter 2015 Conference Call Scheduled For Tuesday, November 3, 2015 At 10:00 AM ET

Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, November 3, 2015 to review third quarter 2015 results.